NASDAQ:NXTC NextCure (NXTC) Stock Price, News & Analysis $4.90 -0.19 (-3.63%) As of 08/8/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About NextCure Stock (NASDAQ:NXTC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NextCure alerts:Sign Up Key Stats Today's Range$4.85▼$5.2850-Day Range$4.74▼$8.1752-Week Range$2.69▼$20.16Volume14,772 shsAverage Volume326,236 shsMarket Capitalization$13.05 millionP/E RatioN/ADividend YieldN/APrice Target$25.50Consensus RatingModerate Buy Company Overview NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. Read More NextCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreNXTC MarketRank™: NextCure scored higher than 88% of companies evaluated by MarketBeat, and ranked 112th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingNextCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNextCure has only been the subject of 3 research reports in the past 90 days.Read more about NextCure's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NextCure are expected to grow in the coming year, from ($1.87) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NextCure is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NextCure is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNextCure has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.36% of the float of NextCure has been sold short.Short Interest Ratio / Days to CoverNextCure has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NextCure has recently decreased by 90.74%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNextCure does not currently pay a dividend.Dividend GrowthNextCure does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.08 Percentage of Shares Shorted1.36% of the float of NextCure has been sold short.Short Interest Ratio / Days to CoverNextCure has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NextCure has recently decreased by 90.74%, indicating that investor sentiment is improving significantly. News and Social Media1.4 / 5News Sentiment-0.53 News SentimentNextCure has a news sentiment score of -0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for NextCure this week, compared to 0 articles on an average week.Search Interest3 people have searched for NXTC on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NextCure insiders have not sold or bought any company stock.Percentage Held by Insiders17.90% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NextCure's insider trading history. Receive NXTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter. Email Address NXTC Stock News HeadlinesNextCure Reports Q2 2025 Results and Strategic UpdatesAugust 7 at 12:45 AM | tipranks.comNextCure (NXTC) Q2 Loss Widens 71%August 7 at 11:32 PM | fool.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 10 at 2:00 AM | Brownstone Research (Ad)NextCure Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 7 at 4:18 PM | globenewswire.comNextCure (NXTC) Projected to Post Quarterly Earnings on ThursdayJuly 31, 2025 | americanbankingnews.comNextCure presents new preclinical data on osteogenesis imperfecta treatmentJuly 25, 2025 | msn.comNextCure stock soars after positive data for bone disease treatmentJuly 25, 2025 | investing.comNextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease TreatmentJuly 25, 2025 | msn.comSee More Headlines NXTC Stock Analysis - Frequently Asked Questions How have NXTC shares performed this year? NextCure's stock was trading at $9.2520 at the beginning of 2025. Since then, NXTC shares have decreased by 47.4% and is now trading at $4.87. How were NextCure's earnings last quarter? NextCure, Inc. (NASDAQ:NXTC) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($11.29) earnings per share for the quarter, missing the consensus estimate of ($4.62) by $6.67. When did NextCure's stock split? NextCure's stock reverse split on the morning of Monday, July 14th 2025.The 1-12 reverse split was announced on Friday, June 20th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, July 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did NextCure IPO? NextCure (NXTC) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO. Who are NextCure's major shareholders? NextCure's top institutional shareholders include Geode Capital Management LLC (8.57%). View institutional ownership trends. How do I buy shares of NextCure? Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NextCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that NextCure investors own include Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings8/07/2025Today8/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NXTC CIK1661059 Webwww.nextcure.com Phone(240) 399-4900FaxN/AEmployees90Year Founded2015Price Target and Rating Average Price Target for NextCure$25.50 High Price Target$36.00 Low Price Target$15.00 Potential Upside/Downside+423.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($21.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.65 million Net MarginsN/A Pretax MarginN/A Return on Equity-92.82% Return on Assets-76.69% Debt Debt-to-Equity RatioN/A Current Ratio10.26 Quick Ratio10.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$28.06 per share Price / Book0.17Miscellaneous Outstanding Shares2,680,000Free Float2,197,000Market Cap$13.05 million OptionableOptionable Beta1.25 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:NXTC) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAUGUST 13: New IPO 350X Bigger Than Amazon IPO?Starlink could be Elon Musk’s most ambitious venture yet—and its IPO is expected to be the biggest in history....Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.